<DOC>
	<DOCNO>NCT02620618</DOCNO>
	<brief_summary>Intravitreal injection 2 mg infliximab prove safe animal model ( rabbit primate ) . These study show evidence intraocular inflammation toxicity clinical , electrophysiological , histopathological examination 90 day even 3 repeat monthly injection . However , study conduct Rassi et al one report development severe intraocular inflammation one eye 12 rabbit eye 90 day follow 3 intravitreal injection ( 2mg monthly ) . Unfortunately , clinical study conduct patient , far , raise serious concern safety adverse effect . These clinical study show various inconsistent result term safety efficacy intravitreal infliximab . These study conduct patient refractory well naïve case age relate macular degeneration choroidal neovascularization ( AMD CNV ) , diabetic macular edema ( DME ) , central retinal vein occlusion ( CRVO ) , angiomatous malformation , pseudophakic macular edema , uveitis . The dos use range 0.5mg 2mg . The initial study Theodossaidis et al 2009 report intraocular inflammation 3 patient receive 2 intravitreal injection 1 2 mg refractory AMD CNV 7 month follow period . ( 8 ) Later several clinical study report severe intraocular inflammation follow intravitreal injection infliximab non-uveitic patients.These collect data initiate call cautious use intravitreal infliximab . On hand , study investigate intravitreal infliximab uveitis patient show improvement vision , reduction macular thickness optical coherence tomography ( OCT ) , reduction inflammation . In study , investigate safety efficacy 3 consecutive intravitreal infliximab injection ( 1 mg/0.05 mL , 6 week apart ) carefully select group patient refractory uveitis Behcet 's disease .</brief_summary>
	<brief_title>Intravitreal Infliximab Refractory Uveitis Behcet 's Disease : A Safety Efficacy Clinical Study</brief_title>
	<detailed_description>Approval study obtain hospital 's ethical committee . The study design methodology follow tenet Declaration Helsinki . All patient provide write informed consent receive thorough explanation study design , aim , off-label use infliximab , potential risk , benefit . This prospective non-comparative interventional study . The study conduct 20 eye 20 patient refractory posterior uveitis Behçet 's disease receive 3 consecutive intravitreal injection infliximab ( 1 mg/0.05 ml ) 6 week apart . Behçet 's disease diagnose base International Criteria Behçet 's Disease ( ICBD ) . Patients subject follow initial examination : best-corrected visual acuity ( BCVA ) measurement ; slit-Lamp examination ; measure intraocular pressure ( IOP ) Goldman applanation tonometry ; dilate fundus examination indirect ophthalmoscope ; slit-lamp biomicroscopy include vitritis grading ( 0-4 ) presence absence vasculitis , retinitis papillopathy . Patients also follow baseline : fluorescein angiography ( FFA ) , ERG , central foveal thickness ( CFT ) OCT ( Stratus III OCT ; Carl Zeiss , Dublin , CA ) . Grading vitritis follow : Grade 0 : Good view NFL ( nerve fibre layer ) , Grade +1 : clear optic nerve &amp; vessel hazy NFL , Grade +2 : optic nerve &amp; vessel hazy , Grade +3 : view optic nerve , Grade +4 : optic nerve view . Follow clinical examination day 1 , week 2 , 4 , 6 , 8 , 12 18 . Each follow visit include : BCVA , slit-Lamp examination , IOP , dilate fundus examination grade vitritis ( 0-4 ) , presence absence vasculitis , retinitis papillopathy . CFT OCT , ERG do 4 , 12 18 week . FFA do discretion examiner every post-injection evaluation . The intravitreal dose infliximab use study 1mg/0.05ml . Animal study show intravitreal infliximab dose 2mg safe clinically , electrophysiological histopathological examination . These finding maintain 3 month 3 monthly injection . However , clinical trial severe intraocular inflammation elicit even single low dose 0.5mg non-uveitic eye . Since 1 mg dose show effective control inflammation one study , decide use dose avoid 1.5mg 2mg dos . Drug preparation : A vial containing 100 mg commercially available infliximab powder ( Remicade Janssen Pharmaceutical Egypt ) reconstitute 5 mL sterile water , 0.05 mL solution ( 1mg infliximab ) use patient place tuberculin syringe use aseptic technique . The remain syrinx keep sterile package 2-8ºC 6 week . Injection technique : The eye prepared standard fashion use 5 % povidone-iodine , eyelid speculum stabilize eyelid , injection 1mg ( 0.05 mL ) perform 3.5mm 4 mm posterior limbus , infero-temporal par plana 30-gauge needle topical anesthesia . After injection , retinal artery perfusion check patient instructed administer topical antibiotic 3 day . All patient give detailed post-injection instruction ask call promptly pain significant change vision occur . Patients see follow ups repeat injection give 6 week interval re-injection criterion meet : 1 ) No evidence significant ERG change , 2 ) No evidence adverse effect drug , 3 ) Signs anatomical and/or functional improvement first 6 week . Statistical Analysis : Data statistically describe term mean ± standard deviation ( ±SD ) , median range , frequency ( number case ) percentages appropriate . Comparison numerical variable study group do use Freidman 's test Conover test pair ( match ) sample posthoc multiple 2-group comparison . For compare categorical data , Chi square ( ±2 ) McNemar test perform . GCC do use McNemar test . Agreement test use kappa statistic . Correlation various variable do use Spearman rank correlation equation . P value less 0.05 consider statistically significant . All statistical calculation do use computer program SPSS ( Statistical Package Social Science ; SPSS Inc. , Chicago , IL , USA ) version 15 Microsoft Windows Stats Direct statistical software version 2.7.2 MS Windows , StatsDirect Ltd. , Cheshire , UK .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Inclusion criterion : Refractory posterior uveitis patient Behçet 's disease . Exclusion criterion : 1 . Patients receive received systemic infliximab TNFα inhibitor 2 . Patients uncontrolled systemic Behçet 3 . Patients receive previous intravitreal steroid ( &lt; 6 month ) 4 . Patients severe medium opacity 5 . Patients previous history ocular surgery cataract surgery 6 . Cataract surgery within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>intravitreal infliximab</keyword>
	<keyword>ocular behcets</keyword>
	<keyword>refractory posterior uveitis</keyword>
</DOC>